The Role of Polyethylene Design on Postoperative TKA Flexion: An Analysis of 1534 Cases
The range of motion after TKA depends on many patient, surgical technique, and implant factors. Recently, high-flexion designs have been introduced as a means of ensuring or gaining flexion after TKA. We therefore evaluated factors affecting postoperative flexion to determine whether implant design...
Gespeichert in:
Veröffentlicht in: | Clinical orthopaedics and related research 2010-01, Vol.468 (1), p.108-114 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The range of motion after TKA depends on many patient, surgical technique, and implant factors. Recently, high-flexion designs have been introduced as a means of ensuring or gaining flexion after TKA. We therefore evaluated factors affecting postoperative flexion to determine whether implant design influences longterm flexion. We prospectively collected data on patients receiving a primary Genesis II™ total knee replacement with a minimum of 1-year followup (mean, 5.4 years; range, 1–13 years). We recorded pre- and postoperative outcome measures, patient demographics, and implant design (cruciate retaining [CR, n = 160], posterior stabilized [PS, n = 1177], high-flex posterior stabilized [HF-PS, n = 197]). Backward stepwise linear regression modeling identified the following factors affecting postoperative flexion: preoperative flexion, gender, body mass index, and implant design. Independent of gender, body mass index, and preoperative flexion, patients who received a HF-PS and PS design implant had a mean of 8° and 5° more flexion, respectively, than those who received a CR implant. Patients with low flexion preoperatively ( 120°) were most likely to maintain or lose flexion postoperatively. Controlling for implant design, patients with high flexion preoperatively (> 120°) were more likely to gain flexion with the HF-PS design implant (HF-PS = 32.0%; PS = 15.1%; CR = 4.5%).
Level of Evidence:
Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence. |
---|---|
ISSN: | 0009-921X 1528-1132 |
DOI: | 10.1007/s11999-009-1127-9 |